Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Summary

The primary objective is to determine the maximum tolerated dose of AVE9633 and to characterize the dose limiting toxicity(ies). Secondary objectives are to determine the anti-leukemia activity, the global safety and the PK profile.

Timeline

Start

2007-09

Primary completion

2008-08

Completion

2008-08

Outcome

Outcome not reported

Stopped: “due to absence of evidence of clinical activity up to toxic doses”

Drugs

Indications